Skip to main content

Pfizer Inc(PFE-N)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - Mon Sep 18, 6:00AM CDT

Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD

Phase 2 head-to-head portion of the study to commence enrollment immediately


Provided Content: Content provided by The Globe and Mail was not involved, and material was not reviewed prior to publication.